menu
U.S. Vaccine Market Growth And Trends 2022
U.S. Vaccine Market Growth And Trends 2022
[156 Pages] U.S. vaccines market is estimated to account for US$ 19,355.2 Mn in terms of value in 2020. U.S. Vaccine Market by Product Type and End User 2020-2027

Menu

COVID-19 Tracker Who We Are Contact US Careers

Logo

U.S. Vaccine Market

Request Free Sample Copy Download PDF Brochure

  1. all home image
  2. Market Insight
  3. U.S. Vaccine Market Analysis

Published On : Jul 2020

all report title image

U.S. Vaccine Market Analysis

U.S. Vaccine Market, By Product Type (Human Vaccine (Pediatric Vaccines, Adult & Adolescent Vaccines, Other Human Vaccines), Animal Vaccine (Livestock Vaccines, Companion Animal Vaccines, Other Animal Vaccines)), By End User (Hospitals, Clinics Vaccination, Centers) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. Inactivated, attenuated, toxoid, subunit, conjugate, heterotypic, experimental, and valence are the types of vaccines.

U.S. vaccines market is estimated to account for US$ 19,355.2 Mn in terms of value in 2020 and is estimated to account for US$ 27,947.4 Mn by the end of 2027.

U.S. Vaccines Market: Drivers

Emergence of Covid-19 is expected to propel growth of the U.S. vaccines market over the forecast period. For instance, in the U.S. from January 20, 2020 to 6:01 pm CEST, 6 July 2020, there have been 2,833,552 confirmed cases of COVID-19 with 129,408 deaths, as reported to the World Health Organization.

Moreover, R&D initiatives for new vaccines is also expected to aid in growth of the market. For instance, in March 2020, IQVIA and Quest Diagnostics, through its joint venture Q2 Solutions, collaborated with the University of Texas Medical Branch to develop a novel assay for COVID-19 tests for rapid development of a Coronavirus vaccine.

Human vaccine held dominant position in the U.S. vaccines market in 2019, accounting for 81.7% share in terms of value, followed by animal vaccine respectively.

Figure 1. U.S. Vaccines Market Share (%), by Value, by Vaccine Type, 2019

U.S. Vaccine  | Coherent Market Insights

U.S. Vaccines Market: Restraints

High cost of refrigeration of vaccines is expected to hinder growth of the market. For vaccines, refrigeration is mandatory to prevent alteration of their chemical structure mainly due to contact with water and humidity resulting in ineffective medications. Maintaining this cold chain from production until they are used in treatment is a costly process accounting for about 80% of the price of vaccinations.

Moreover, short functional shelf life of certain vaccines is also expected to limit the market growth.

Sanofi Pasteur, GlaxoSmithKline Plc, Merck & Company Incorporated, Pfizer Incorporated, AstraZeneca plc, and Boehringer Ingelheim

U.S. Vaccines Market: Opportunities 

Building registry platform and database regarding COVID-19 is expected to offer lucrative growth opportunities for players in the U.S. vaccines market. For instance, in April 2020, Clara Health, a software startup, collaborated with Lyft, Inc., a ridesharing company, and VSC, a public relations agency, to build the registry platform and database to connect COVID-positive and -negative individuals with clinical trials for diagnostics, treatment and vaccine discovery.

Moreover, initiatives to promote R&D in poultry is also expected to aid in growth of the market.  For instance, in May 2020, The U.S. Poultry Foundation awarded a US$ 7,000 grant to the University of North Georgia to recruit students into the poultry science program.

U.S. vaccines market was valued at US$ 18,367.0 Mn in 2019 and is forecast to reach a value of US$ 27,947.4 Mn by 2027 at a CAGR of 5.4% between 2020 and 2027.

Figure 2. U.S. Vaccines Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

U.S. Vaccine  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the market are focused on adopting partnership and collaboration strategies to expand their product portfolio. For instance, in April 2020, Sanofi Pasteur collaborated with GSK to develop an adjuvanted vaccine for COVID-19.

Stringent regulations that promote vaccination are boosting the market growth. For instance, in January 2020,            the Government of New Jersey, U.S., mandated college students to be vaccinated against bacterial meningitis as a condition for attending an institution.

Regulations

The Center for Biologics Evaluation and Research (CBER) is the central regulatory agency responsible for ensuring purity, safety and efficacy of vaccines in the U.S.

U.S. Vaccines Market: Competitive Landscape

Major players operating in the U.S. vaccines market include, Sanofi Pasteur, GlaxoSmithKline Plc, Merck & Company Incorporated, Pfizer Incorporated, AstraZeneca plc, and Boehringer Ingelheim.

U.S. Vaccines Market: Key Developments

Major players in the market are focused on approval and launch of new vaccines to expand their product portfolio. For instance, in January 2020, Boehringer Ingelheim's U.S. Animal Health Business launched a vaccine, VAXXITEK HVT+IBD+ND that offers protection against Marek's Disease, Infectious Bursal Disease (classic and variant types) and Newcastle Disease.

Similarly, in December 2019,  NewLink Genetics Corporation received the U.S. FDA approval for ERVEBO or Zaire Ebola virus vaccine V920.

Vaccines are biologically prepared products, which provide active acquired immunity to diseases such as cholera, polio, rotavirus, smallpox, yellow fever and others. A vaccine comprise an agent resembling to the disease causing microorganism. The vaccines are generally developed from live attenuated or killed forms of the disease causing microorganism, its toxins, or its surface proteins.

Restraints of the U.S. Vaccine Market

Major factors hampering the growth of the U.S. vaccine market during the forecast period constitutes of short functional shelf life of certain vaccines, and high costs.

Key features of the study:

Detailed Segmentation

 “*” marked represents similar segmentation in other categories in the respective section.

The measles and rubella (MR) vaccine, which protects again...

Bovine serum albumin (BSA or "Fraction V") is a serum albu...

As coronavirus cases continue to prevail across the globe,...

Plant serves as an important source to produce cost-effect...

Joining thousands of companies around the world committed to making the Excellent Business Solutions.